Company Overview and News

0
India’s BEL opens Vietnam office to boost exports

2018-06-14 janes
India’s state-owned Bharat Electronics Limited (BEL) has opened a representative office in Hanoi, Vietnam, to pursue exports in the country and the wider Southeast Asia region.
BHQRY 500049 BEL

17
Second tranche of Bharat-22 ETF on June 19; govt to get up to Rs 8,400 cr

2018-06-13 moneycontrol
The Finance Ministry will launch the second tranche of Bharat-22 exchange traded fund (ETF) on June 19 which will help raise up to Rs 8,400 crore from the markets. The issue will open for anchor investors on June 19 and for other institutional and retail investors the next day. The ETF follow on offer will remain open till June 22.
INDIANB BHQRY AXB 532814 533278 532215 AXBKY 533106 AXBA 532178 OIL AXISBANK ENGINERSIN 500049 BEL CLNDY COALINDIA

17
Second tranche of Bharat-22 ETF on June 19; govt to get up to Rs 8,400 cr

2018-06-13 thehindubusinessline
The Finance Ministry will launch the second tranche of Bharat-22 exchange traded fund (ETF) on June 19 which will help raise up to ₹8,400 crore from the markets.
INDIANB BHQRY AXB 532814 533278 532215 AXBKY 533106 AXBA 532178 OIL AXISBANK ENGINERSIN 500049 BEL CLNDY COALINDIA

0
India points to advances in defence manufacturing

2018-06-06 janes
The Indian Ministry of Defence (MoD) has pointed to improvements across a range of defence-industrial key performance indicators. These were contained in the MoD’s ‘ebook’ of major achievements, highlighting developments over the past four years under the Narendra Modi administration, which was published on 5 June.
BHQRY 500049 BEL

0
Bharat Electronics Limited - Updates

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHQRY 500049 BEL

0
Bypolls 2018: After failure of EVMs and VVPATs, questions been raised for their use in 2019 general elections

2018-06-01 freepressjournal.in
New Delhi: The Election Commission’s own admission of the large-scale malfunctioning of the electronic voting machines and voter verifiable paper audit trails is shocking, particularly when they were used for just four Lok Sabha and ten Assembly by-elections, putting a question mark on their use in a general election.
BHQRY 500049 BEL

0
Bharat Electronics Limited - Investor Presentation

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHQRY 500049 BEL

0
Bharat Electronics slumps 4.4% on weak results

2018-05-30 thehindubusinessline
Shares of Bharat Electronics fell on weak March-quarter results. The stock fell as much as 4.4 per cent to Rs 117.35, its biggest intraday percentage decline since May 16.
BHQRY FORTIS 500049 BEL 532843

0
Bharat Electronics Limited - Dividend

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHQRY 500049 BEL

0
Bharat Electronics Limited - Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHQRY 500049 BEL

0
Bharat Electronics Limited - Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHQRY 500049 BEL

0
Defence industry may see spectacular growth after 2019 General Elections, says LT#39;s Jayant Patil

2018-05-16 moneycontrol
Jayant D Patil spearheaded L&T’s foray into the defence industry in 1986, at a time few other private companies saw any promise in the heavily regulated industry. Patil, who joined the infrastructure heavy weight straight after passing out from IIT Mumbai in 1978, developed long-term relationships with the DRDO, and the Navy, among other defence establishments.
BHQRY 500049 BEL

0
Congress alleges scam in CCTV camera project, says AAP government compromised national security

2018-05-11 freepressjournal.in
New Delhi: The AAP government has “compromised national security” by giving the contract of installing 1.5 lakh CCTV cameras in the national capital to a Chinese company, Delhi Congress president Ajay Maken alleged today and demanded the resignation of Chief Minister Arvind Kejriwal.
BHQRY 500049 BEL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...